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Human evolution is characterized by the rapid expansion of brain
size and drastic increase in cognitive capabilities. It has long been
suggested that these changes were accompanied by modiﬁcations
of brain metabolism. Indeed, human-speciﬁc changes on gene ex-
pression or amino acid sequence were reported for a number of
metabolic genes, but actual metabolite measurements in humans
and apes have remained scarce. Here, we investigate concentra-
tions of more than 100 metabolites in the prefrontal and cerebellar
cortex in 49 humans, 11 chimpanzees, and 45 rhesus macaques of
different ages using gas chromatography–mass spectrometry (GC-
MS). We show that the brain metabolome undergoes substantial
changes, both ontogenetically and evolutionarily: 88% of detected
metabolites show signiﬁcant concentration changes with age,
whereas 77% of these metabolic changes differ signiﬁcantly
among species. Although overall metabolic divergence reﬂects
phylogenetic relationships among species, we found a fourfold
acceleration of metabolic changes in prefrontal cortex compared
with cerebellum in the human lineage. These human-speciﬁc met-
abolic changes are paralleled by changes in expression patterns of
the corresponding enzymes, and affect pathways involved in syn-
aptic transmission, memory, and learning.
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Human evolution is characterized by rapid expansion of brainsize and increase in cognitive capabilities, leading to the
emergence of unique and complex cognitive skills. These changes
have long been associated with changes in brain metabolism, in
particular with respect to increased energy demand (1). Large
brains are metabolically costly. Thus, humans allocate approxi-
mately 20% of their total energy to the brain, compared with 11–
13% for apes and 2–8% for other mammalian species (2). This
increased metabolic demand has been associated with elevated
expression of genes involved in neuronal functions and energy
metabolism (3, 4). These changes may have been evolutionary
advantageous, as indicated by signatures of positive selection
reported for the amino acid changes, which occur in the mito-
chondrial electron-transport chain proteins, in anthropoid pri-
mates and humans, as well as elevated expression of the energy
metabolism pathways in the human brain (5, 6). On the histo-
logical level, human brains show the largest density of glia cells
relative to neurons in the prefrontal cortex, which provides an
indirect indication of increased neuronal metabolic demand (7).
Changes in brain metabolism are also implicated in neuro-
psychiatric disorders, such as schizophrenia, which affect some of
the human-speciﬁc cognitive abilities (8, 9). Furthermore, direct
measurements of 21 metabolites in the prefrontal cortex of adult
human controls compared with human schizophrenia patients,
chimpanzees, and rhesus macaques, carried out using proton
NMR spectroscopy have shown signiﬁcant overlap between hu-
man-speciﬁc evolutionary changes and metabolic differences
between controls and schizophrenia patients (10). Notably, this
study has identiﬁed not only energy metabolites, such as lactate
and creatine, but also metabolites related to neurotransmission,
such as choline and glycine, as being altered in both human
evolution and in disease. Taken together, these observations
suggest that diverse metabolic changes might have been impor-
tant to the establishment and maintenance of the human-speciﬁc
cognitive abilities.
Here, we used a combination of gas chromatography–mass
spectrometry (GC-MS) metabolomics and quantitative label-free
proteomics to measure concentrations of more than 100 metab-
olites and ∼2,000 proteins in brains of humans, chimpanzees,
and rhesus macaques. Application of GC-MS methodology to
metabolic proﬁling in the human tissues, including brain, was
successfully introduced almost 30 y ago (11). This methodology
provides good resolution for relatively small, thermally stable
compounds that can be made volatile through derivatization (12).
It must be noted, however, that although GC-MS methodology
can potentially resolve thousands of metabolites, compound de-
rivatization and fragmentation during the procedure preclude
direct metabolite identiﬁcation. Instead, the methodology relies
on using pure compounds as standards, thus leaving a number of
metabolites detected in the procedure unidentiﬁed.
Using GC-MS methodology, we studied metabolic differences
among humans, chimpanzees, and macaques at different ages in
two functionally and evolutionary distinct brain regions: superior
frontal gyrus of the prefrontal cortex (PFC) and lateral part of the
cerebellar cortex (CBC). PFC is a brain region that emerged re-
cently during primate evolution. It is implicated in complex as-
sociative functions including reasoning, planning, social behavior,
and general intelligence (13–15). Furthermore, the PFC has been
shown to undergo greater expansion at the gross anatomy level on
the human evolutionary lineage than the CBC (16). Although
CBC has also evolved considerably in primates (17, 18), its in-
volvement in processing and execution of human-speciﬁc cogni-
tive tasks is not yet well understood.
Results
Estimation of Metabolic Variation in the Primate Brain. To directly
assess the extent of metabolic changes between human brain and
brains of other primate species, we measured metabolite levels in
postmortem PFC and CBC samples from 49 humans, 11 chim-
panzees, and 45 rhesus macaques, using GC-MS (Table S1).Many
phenotypic parameters, such as maximal life span, age of sexual
maturity, and brain growth curves differ between humans, chim-
panzees, and rhesus macaques (19, 20). This makes it difﬁcult to
match samples with respect to age among these three species. To
overcome this problem and to estimate changes in metabolite
levels during brain development, maturation and aging, we sam-
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pled individuals of different age, covering most of the species’
lifespan: humans 0–98 y, chimpanzees 0–40 y, and macaques
0–28 y (Fig. S1 and Table S1). Tominimize sampling variation, for
all individuals we took care to sample gray matter only. To min-
imize technical variation, we measured each sample twice.
Using GC-MS methodology, we detected a total of 232
metabolites, some present in a single individual. Out of these, we
focused on 118 metabolites, 61 annotated and 57 unknown,
detected in more than 80% of samples in at least one brain region
in one or more of the three species (Table S2). For these metab-
olites we found good agreement in metabolite measurements be-
tween replicates in all three species and all brain regions (median
Pearson r> 0.95, P< 0.0001), indicating high reproducibility of the
GC-MS measurements (Fig. S2).
Besides technical reproducibility, another concern is the rele-
vance of metabolite measurements made in postmortem brain
tissue to in vivo metabolite concentrations. Previous studies that
have used proton magnetic resonance spectroscopy in human and
rat brain biopsy samples have shown that concentrations of
metabolites associated with anaerobic glycolysis, such as glucose,
alanine, glutathione and lactate, change after death (21–24). In
rat brain, postmortem delay also leads to concentration changes
of dopamine, norepinephrine, and serotonin in the occipital
cortex. This effect, however, was not shared by all brain regions,
as serotonin levels remained stable over an 18-h postmortem
interval in the cingulate cortex (25). Furthermore, concentrations
of many metabolites, such as myo-inositol, creatine, glutamine,
glutamate, N-acetylaspartate, and taurine were shown to remain
stable in the postmortem brain tissue over long time intervals (22,
23, 26, 27). Similarly, experiments quantifying brain polyamines,
such as spermine, spermidine, and putrescine, in postmortem
human brain using GC-MS did not report any signiﬁcant re-
lationship between these metabolite concentrations and post-
mortem interval (28). To estimate the effect of postmortem delay
on metabolite concentrations in our study, we took advantage of
the fact that, with the exception of one sample with approximately
a 5-h postmortem delay, all rhesus macaque brain tissues were
collected and frozen within 20 min after death (Table S1). By
examining the proﬁle of each metabolite among the macaque
samples, we identiﬁed 26metabolites with signiﬁcant differences in
concentration between replicate measurements taken from the
macaque individual with prolonged postmortem delay and meas-
urements taken from all other samples in at least one brain region
(Fig. S3). In agreement with previous studies, many of these
metabolites were involved in glucose metabolism (Table S3). Con-
sequently, we excluded these metabolites from all further analyses.
Some of the human and chimpanzee samples used in our study
have a postmortem delay exceeding the 5-h interval tested using
macaque samples. Still, in macaques, the vast majority of metab-
olites showed no indication of postmortem-induced concentration
change after 5 h, demonstrating their long-term stability (Fig. S4).
Furthermore, our assignment of metabolic changes to the evolu-
tionary lineages requires similarity between macaque metabolite
measurements over the lifespan and metabolic measurements in
either human or chimpanzee brains. As macaque data are not
affected by postmortem delay, and as human and chimpanzee
samples have no postmortem interval bias, we can largely exclude
postmortem delay as a confounding factor in this study.
To estimate the proportions of the total metabolic variance
explained by species, age, and brain region identity, we used prin-
cipal variance component analysis (29). The differences between
species explained 49% of the total metabolic variation, differences
with age 17%, and differences between two brain regions 9% (Fig.
S5). Accordingly, metabolic differences across species, as well as
differences with age, can be visualized using principal component
analysis in both brain regions (Fig. 1 A and B).
Species-Speciﬁc Metabolic Changes.We next identiﬁed metabolites
showing signiﬁcant concentration changes with age in each spe-
cies using polynomial regression (30). At a false discovery rate
(FDR) <10% (permutation test; SI Appendix), we identiﬁed 48
and 47 metabolites in the CBC and 53 and 26 in the PFC of
humans and macaques, respectively (Table S4). In chimpanzees,
due to the smaller sample size, we found only two and ﬁve age-
related metabolites in CBC and PFC, respectively. Among the
metabolites that change with age in our study, taurine was pre-
viously reported to decrease in concentration during postnatal
brain development in the human and macaque occipital brain
lobe (31). Similarly, in our data we found an approximately linear
decrease with age in taurine concentration in both human and
rhesus macaque PFC and CBC (human PFC: r= −0.37, P < 0.01;
human CBC: r = −0.53, P < 10−5; macaque PFC: r = −0.28, P <
0.05; macaque CBC: r = −0.51, P < 0.001) (Fig. S6). Other than
taurine, we found no reported primate brain time-series data that
involved age-related metabolites as identiﬁed in our study.
We next tested whether metabolites change differently with
age among the three species. Here, we focused on metabolites
showing different concentration proﬁles over the species’ life-
span, rather than on mean concentration differences alone. Given
the large and comparable numbers of human and rhesus ma-
caque samples, we ﬁrst identiﬁed metabolites with signiﬁcant
difference in concentration proﬁles between these two species
in each brain region. Using analysis of covariance (ANCOVA) with
linear, quadratic, and cubic models, we found 49 metabolites in
PFC and 43 in CBC at FDR < 1% (permutation test; SI Appendix).
Of these metabolites, 30 were different between humans and
macaques in both brain regions (Fig. S7). Thus, both PFC and
CBC metabolome show substantial divergence between humans
and macaques, with a large proportion of the differences shared
between the two brain regions.
We then used chimpanzee metabolite measurements to sort the
identiﬁed human-macaque metabolic differences into three cate-
gories: (i) human-speciﬁc changes, (ii) macaque-speciﬁc changes,
and (iii) uncategorized changes. Human-speciﬁc changes were
deﬁned based on signiﬁcant difference between human metabolic
proﬁles and metabolic proﬁles of (but not between) both chim-
panzees and macaques (Wilcoxon test, P < 0.01, FDR < 1%).
Macaque-speciﬁc changes were deﬁned analogously, and there-
fore include changes on both the rhesus macaque evolutionary
lineage, as well as the lineage between the common ancestor of
Old World primates and the common ancestor of humans and
chimpanzees. Uncategorized changes included metabolite pro-
ﬁles that are not described by either of the other two groups. We
found six human-speciﬁc, 33 macaque-speciﬁc, and four unchar-
acterized metabolic changes in CBC. By contrast, in PFC, we
found 24 human-speciﬁc, 20 macaque-speciﬁc, and ﬁve unchar-
acterized metabolic changes. Thus, there is a fourfold excess of
human-speciﬁc metabolic changes in the human PFC compared
with CBC (Figs. 1C, F, andG and 2 and Table S5). This result was
robust with respect to data normalization procedures (Fig. S10).
The additional analyses conﬁrmed the robustness of this re-
sult. Excluding unknown metabolites, we found three metabo-
lites with human-speciﬁc proﬁles in CBC and 11 in PFC (Fig.
S8). Similarly, limiting our analysis to 30 metabolites with sig-
niﬁcant concentration difference between humans and macaque
in both PFC and CBC, we again found more human-speciﬁc
changes in PFC (Fig. 1D). Thus, since the separation from the
last common ancestor of humans and chimpanzees, many more
metabolic changes have taken place on the human evolutionary
linage in PFC than in CBC. By contrast, we found no indication
for faster PFC metabolome evolution, compared with CBC, on
either the macaque evolutionary lineage or the lineage between
the common ancestor of Old World primates and the common
ancestor of humans and chimpanzees (Fig. 1C).
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Furthermore, we repeated the linage assignment analysis using
equal numbers (n = 11) of age-matched individuals across the
three species (Fig. S1). Equalizing sample size across the three
species allowed us to assign metabolic differences to the human
and the chimpanzee evolutionary linage with equal conﬁdence.
To avoid artifacts caused by differences in lifespan duration, we
used the following two approaches to match individuals’ age
across species: (i) stage-of-life approach: scaling ages linearly
within each species to the same maximal lifespan, using 120 y for
humans, 60 for chimpanzees, and 40 for rhesus macaques as
a reference (19); and (ii) chronological approach: using calendar
age directly. Using both approaches, we again found an excess of
human-speciﬁc metabolic changes in PFC and not in CBC (Fig.
1E, Fig. S9, and Table S5). Thus, an acceleration of metabolic
changes in the PFC is speciﬁc to the human evolutionary linage
and is not observed in CBC.
Protein Expression and Metabolic Pathway Analyses. To further test
the validity of the identiﬁed human-speciﬁc metabolic changes
and to assess their functional signiﬁcance, we analyzed the ex-
pression of the corresponding metabolic enzymes in 12 human,
12 chimpanzee, and 12 rhesus macaque PFC samples using label-
free quantitative mass spectrometry.
In humans, chimpanzees and rhesus macaques, we identiﬁed a to-
tal of 1301042, 1004360 and 1151143 peptides, which were mapped
on 10769, 7945, and 9339 IPI peptide sequences, respectively. Re-
quiring at least 10 peptide counts per protein, we detected 2,747
proteins in humans, 2,343 proteins in chimpanzees, and 2,842 pro-
teins in rhesusmacaques.The1,951genesdetected inall three species
(proteinwise FDR < 5%) were used in further analyses.
Using these data, we ﬁrst tested whether metabolic changes
with age found in the human PFC correlate with expression
changes of enzymes directly interacting with these metabolites
(i.e., enzymes connected to metabolites by a single edge in the
KEGG pathway annotation). In total, we found 47 such metab-
olite-enzyme pairs, 21 of them showing signiﬁcant correlation
between metabolite and enzyme concentration changes with age
(Pearson correlation, P < 0.0001, |r|>0.5). Finding such a high
proportion of correlated changes is unexpected (P = 0.001), as
estimated by randomly substituting expression proﬁles of the
enzymes by those of other proteins 1,000 times. The result was
also robust at different correlation coefﬁcient cut-offs (Fig. S11).
Second, we tested whether enzymes directly associated with
metabolites with human-speciﬁc concentration proﬁles (for sim-
plicity: human-speciﬁc metabolites) show more expression dif-
ferences between human and chimpanzee PFC than enzymes
directly associated with metabolites that change with age in the
human PFC but are not human speciﬁc. We found a greater ex-
pression divergence for 13 such enzymes associated with human-
speciﬁc metabolites (one-sided Wilcoxon test, P = 0.003) com-
pared with 24 enzymes associated with non–human-speciﬁc
metabolites (Fig. S12A). Finally, we tested whether enzymes di-
rectly associated with human-speciﬁc metabolites show more
human-speciﬁc expression than enzymes directly associated with
non–human-speciﬁc metabolites, by estimating the ratio between
their human–macaque and chimpanzee–macaque expression di-




Fig. 1. Metabolite variation among species. (A and B) Principal component analysis of CBC and PFC metabolomes of the three species based on 92 detected
metabolites. Each circle represents an individual. Size of circles is proportional to the individuals’ ages, with larger circles corresponding to older individuals.
Colors represent species: red, human; purple, chimpanzee; blue, rhesus macaque. (C–E) Proportions of human-speciﬁc (red), macaque-speciﬁc (gray), chim-
panzee-speciﬁc (blue), and uncategorized metabolites (white) among the following: (C) the 43 and 49 metabolites with signiﬁcant difference in concen-
tration proﬁles between humans and rhesus macaques in CBC and PFC, respectively, identiﬁed using the full set of individuals; (D) the 30 metabolites with
signiﬁcant difference in concentration proﬁles between humans and rhesus macaques in both CBC and PFC; (E) the 25 and 17 metabolites with signiﬁcant
difference in concentration proﬁles among humans, chimpanzees, and rhesus macaques identiﬁed in CBC and PFC, respectively, using the subsets of 11
individuals per species matched using stage-of-life approach (SI Appendix). Numbers indicate numbers of metabolites in corresponding category. (F and G)
Hierarchical clustering based on concentration proﬁles of 24 metabolites classiﬁed as human speciﬁc in PFC and six metabolites classiﬁed as human speciﬁc in
CBC. Column headers indicate species: Ch, chimpanzee; Hu, human; Ma, rhesus macaque. Red and blue color intensities indicate metabolite concentration
levels at different age normalized to mean equal a value of 0 and SD equal a value of 1 within each brain region.







speciﬁc metabolites, this ratio was signiﬁcantly greater (one-sided
Wilcoxon test, P = 0.004) (Fig. S12B). Thus, we observed signif-
icant agreement between human-speciﬁc metabolic proﬁles in the
PFC and expression of the corresponding enzymes in terms of
both ontogenetic changes and evolutionary divergence.
To determine which pathways are associated with human-
speciﬁc metabolic changes, we ﬁrst mapped the detected pro-
teins onto the KEGG pathways containing at least one human-
speciﬁc metabolite and more than 10 proteins. This resulted in
13 KEGG pathways that include ﬁve metabolites (glutamate,
histidine, spermidine, oxoproline, and hexadecanoic acid) and
209 proteins. Four pathways had greater than expected human-
speciﬁc protein expression divergence: long-term potentiation
(P = 0.039), neuroactive ligand-receptor interaction (P = 0.015),
alanine, aspartate, and glutamate metabolism (P = 0.022), and
β-alanine metabolism” (P= 0.012) (Fig. 3A and Fig. S13). For all
four pathways, Q values were <0.02, indicating signiﬁcance of
results given the number of pathways tested.
These pathways are not independent, but share common genes
and a common metabolite, i.e., glutamate, which is present at
lower concentrations in humans than in chimpanzees or mac-
aques, particularly at the ﬁrst years of life (Figs. 2B and 3B).
Besides glutamate, two other metabolites with human-speciﬁc
proﬁles in PFC, histidine, and spermidine, are involved in the
β-alanine metabolism pathway.
Discussion
Our results show that human, chimpanzee, and macaque brain
metabolomes change substantially with age: Speciﬁcally, 88% of
the metabolites change their concentration signiﬁcantly over the
course of lifespan in at least one species or one brain region
(Table S6). Many of these metabolic changes with age differ
signiﬁcantly among the three species (53% and 47% in PFC and
CBC, respectively). Considering the two brain regions together,
77% of metabolic changes with age differed among species
(Table S6). Large numbers of signiﬁcant metabolic changes with
age and differences among species are in line with substantial
proportion of the total metabolic variance explained by these
factors (17% and 49%, respectively; Fig. S5).
It must be noted, however, that most of the identiﬁed meta-
bolic differences between species are not due to a difference in
the pattern of concentration changes with age. Instead, 67% of
metabolic changes in PFC and 82% in CBC reﬂect differences in
the rate of age-related changes and/or differences in the mean
metabolite concentration among species (Table S9). Thus, the
majority of metabolic changes with age, especially in CBC, follow
the same trajectory in all three species.
Our main result is the discovery of an approximately fourfold
excess of metabolic changes in the PFC on the human evolutionary
lineage. By contrast, CBC shows no such acceleration. This result
is robust to choice of the normalization procedure, as well as
chronological and stage-of-life age-matching subsets. Further-
more, we observed signiﬁcant agreement between concentration
A
B
Fig. 2. Metabolites with human-speciﬁc concentration proﬁles. Shown are the six metabolites with human-speciﬁc concentration proﬁles in CBC (A) and 24
metabolites with human-speciﬁc concentration proﬁles in PFC (B). Points show metabolite concentrations in each individual. Colors represent species: red,
humans; purple, chimpanzees; and blue, rhesus macaques. Lines are spline curves ﬁtted to data points with 3 df. The x axis shows individuals’ ages in years.
The y axis shows normalized GC-MS measurements representing metabolite concentrations. Titles show metabolite annotation. Unannotated metabolites are
labeled “unknown.”
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proﬁles of metabolites in the human PFC and expression proﬁles
of the corresponding metabolic enzymes. As protein expression
measurements were carried out using independently dissected
tissue samples and different methodologies, signiﬁcant corre-
spondence between protein and metabolic changes underscores
the validity of the results.
Importantly, PFC and CBC samples used in our study come
from the same individuals. This fact largely excludes individual
demographic variables, such as postmortem delay, cause of death,
medication, and so on, as causative factors for the difference in
numbers of human-speciﬁc metabolic changes between PFC and
CBC. Still, if environmental factors had a different effect on PFC
and CBC metabolism, this could result in observed differences
between the two brain regions.
Some aspects of environment and lifestyle, such as diet and life in
captivity, could be argued to be more similar between chimpanzees
and macaques, consequently making humans more distinct. To
estimate the extent to which the species-speciﬁc metabolic changes
might be caused by these environmental factors, we collected 37
metabolites reported to be affected by diet and 71 by exercise
(Table S7). Using Fisher’s exact test, we did not ﬁnd signiﬁcant
overrepresentation of diet- or exercise-affected metabolites among
metabolites with species-speciﬁc concentration proﬁles (P > 0.2 in
all tests). Furthermore, reported diet and exercise effects were not
compatible with the species-speciﬁc metabolic pattern that we ob-
served (SI Appendix). Thus, our results provide no indication that
excess of human-speciﬁc metabolic changes found in PFC could be
explained by the inﬂuence of environmental factors.
Glutamate is one of the human-speciﬁc metabolites found in
the PFC in this study. Glutamate release and recycling is a major
metabolic pathway consuming 60–80% of the energy supplied by
the glucose oxidation in the human cerebral cortex (32). Im-
portantly, in the human brain, glutamate pathways play a central
role in both energy metabolism and neurotransmission. Evolu-
tionary changes in glutamate metabolism were previously in-
dicated by the ﬁnding that glutamate dehydrogenase, an enzyme
central to the glutamate and energy metabolism of the cell, has
undergone duplication and subfunctionalization in the common
ancestor of apes and humans, resulting in appearance of an ape-
and human-speciﬁc GLUD2 gene (33). Our ﬁndings show that
additional changes in glutamate metabolism took place in PFC,
but not in CBC, on the human evolutionary lineage.
Speciﬁcally, we ﬁnd that glutamate concentrations were lower
in humans, and particularly in human newborns, compared with
chimpanzees and macaques. Previous studies indicated that
GLUD2 is optimized to rapidly metabolize brain glutamate (34,
35). It is therefore appealing to speculate that low glutamate
concentrations observed in human infants might represent an
evolutionary continuation of the rapid glutamate turnover trend.
Indeed, based on previously published mRNA data (30), we ob-
served higher expression levels of GLUD2 in human newborns
compared with chimpanzee newborns (Fig. S14). This observation
supports our notion that low glutamate levels in human newborns
are caused by higher glutamate turnover. Functional interpretation
of this change, however, is meaningful only in the context of the
large metabolic ﬂux of glutamate release and recycling taking
place in glia and neurons (36, 37). Furthermore, it must be noted
that glutamate concentrations in tissues other than brain were
previously shown to be affected by diet and exercise (38, 39). Al-
though such an environmental effect cannot be fully excluded in
our study, human-speciﬁc changes in glutamate metabolism are
intriguing, and might be an interesting and important subject of
further research.
We must note, however, that even though our analysis covers
more metabolites than other studies conducted to date, it is far
from being comprehensive. Thus, although our ﬁndings indicate
that changes in brain metabolism have contributed to the evo-
lution of human cognition, many important metabolic pathways
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Fig. 3. Pathway analysis of human-speciﬁc metabolites. (A) Shaded bars show median value of the human-speciﬁc protein expression divergence calculated
as ratio of Euclidian distances between human–macaque and chimpanzee–macaque expression proﬁles of protein detected in the 13 KEGG pathways. Each
pathway contains at least one human-speciﬁc metabolite and more than 10 detected proteins. Hatched bars show median human-speciﬁc divergence values
expected by chance. Chance expectations were calculated by randomly assigning the same number of detected proteins to a given pathway, 1,000 times. Error
bars show SD of the chance human-speciﬁc divergence estimates. (B) Network diagram showing four KEGG pathways with signiﬁcantly greater human-
speciﬁc protein expression divergence and three associated human-speciﬁc metabolites: glutamate, histidine, and spermidine. Colors indicate the following:
bright red, proteins with signiﬁcant human-speciﬁc expression; light red, proteins with signiﬁcant human-chimpanzee expression divergence; pink, proteins
with signiﬁcant correlation to the corresponding metabolite proﬁle; gray, detected proteins.







needed to elucidate the entire scope of metabolic changes that
took place on the human evolutionary lineage.
Materials and Methods
Details onmaterials andmethods are provided in SIAppendix. Brieﬂy, samples
were dissected from the frozen postmortem tissue from healthy individuals.
PFC dissections weremade from the frontal part of the superior frontal gyrus.
CBC dissections were taken from the lateral part of the cerebellar hemi-
spheres. For metabolite data, metabolites were extracted from ∼100 mg tis-
sue, using GC-MS measurements as detailed elsewhere (40). All sample
replicates were processed in a completely randomized order to minimize any
possible batch effects. For protein data, proteins were extracted from 100mg
tissue, using label-free quantitative mass spectrometry according to a pre-
viously published method (41). Analysis was performed on an LTQ mass
spectrometer equipped with a metal needle electrospray interface mass
spectrometer (ThermoFinnigan) in a data-dependent collection model (each
full scan followed by 10 MS/MS scans of the most intense ions).
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